Risk of Bacterial Infection in Patients With Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects ofAntibiotics

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1189-1196.e2

  Tandon, Puneeta ^a   Abraldes, Juan G ^a   Keough, Adam ^a   Bastiampillai, Ravin ^a   Jayakumar, Saumya ^a   Carbonneau, Michelle ^a   Wong, Eric ^a   Kao, Dina ^a   Bain, Vince G ^a   Ma, Mang ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Advanced Liver Disease; Antibiotic Resistance; Bleeding; Stratification

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CYANOACRYLATE; OCTREOTIDE; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ACUTE VARICEAL HEMORRHAGE; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CANADA; CHILD PUGH SCORE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENDOSCOPIC THERAPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; NASOGASTRIC TUBE; RETROSPECTIVE STUDY; RISK REDUCTION; SCLEROTHERAPY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; AGED; ALBERTA; BACTERIAL INFECTIONS; COMPLICATION; INCIDENCE; PROCEDURES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERTIARY CARE CENTER;

ADULT; AGED; ALBERTA; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84930380720     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.019     Document Type: Article

References (33)

1. Carbonell N., Pauwels A., Serfaty L., et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004, 40:652-659.
2. El-Serag H.B., Everhart J.E. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000, 95:3566-3573.
3. Chalasani N., Kahi C., Francois F., et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003, 98:653-659.
4. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.
5. Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. NEngl J Med 2010, 362:823-832.
6. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. JHepatol 2010, 53:762-768.
7. Bernard B., Grange J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999, 29:1655-1661.
8. Soares-Weiser K., Brezis M., Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotics. Cochrane Database Syst Rev 2001, 3:CD002232.
9. Chavez-Tapia N.C., Barrientos-Gutierrez T., Tellez-Avila F.I., et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010, 9:CD002907.
10. Garcia-Tsao G., Surawicz C.M. Editorial: Clostridium difficile infection: yet another predictor of poor outcome in cirrhosis. Am J Gastroenterol 2010, 105:114-116.
11. Bajaj J.S., Ananthakrishnan A.N., Hafeezullah M., et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010, 105:106-113.
12. Fraimow H.S., Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011, 27:163-205.
13. Wright G.D. Molecular mechanisms of antibiotic resistance. Chem Commun (Camb) 2011, 47:4055-4061.
14. Wright G.D. Q&A: antibiotic resistance: where does it come from and what can we do about it?. BMC Biol 2010, 8:123.
15. Soriano G., Guarner C., Tomas A., et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992, 103:1267-1272.
16. Blaise M., Pateron D., Trinchet J.C., et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994, 20:34-38.
17. Pauwels A., Mostefa-Kara N., Debenes B., et al. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996, 24:802-806.
18. Lin Y.T., Lo G.H., Lai K.H., et al. Prophylactic antibiotics in cirrhotics with upper gastrointestinal hemorrhage: a prospective, controlled trial. Zhonghua Yi Xue Za Zhi (Taipei) 2002, 65:365-371.
19. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
20. Hingorani A.D., Windt D.A., Riley R.D., et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013, 346:e5793.
21. MacDougall C., Polk R.E. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005, 18:638-656.
22. U.S. Department of Health and Human Services Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013. Available at Accessed September 20, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/.
23. Fernandez J., Acevedo J., Castro M., et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012, 55:1551-1561.
24. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28:26-42.
25. Fernandez J., Gustot T. Management of bacterial infections in cirrhosis. JHepatol 2012, 56(Suppl 1):S1-S12.
26. Cirera I., Bauer T.M., Navasa M., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. JHepatol 2001, 34:32-37.
27. Garcia-Tsao G., Lee F.Y., Barden G.E., et al. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995, 108:1835-1841.
28. Jun C.H., Park C.H., Lee W.S., et al. Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. JKorean Med Sci 2006, 21:883-890.
29. Hong S.N., Kim B.J., Lee S.Y., et al. [Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding]. Taehan Kan Hakhoe Chi 2002, 8:288-296.
30. Hou M.C., Lin H.C., Liu T.T., et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004, 39:746-753.
31. Saab S., Nguyen S., Ibrahim A., et al. Management of patients with cirrhosis in Southern California: results of a practitioner survey. JClin Gastroenterol 2006, 40:156-161.
32. Dancer S.J. How antibiotics can make us sick: the less obvious adverse effects of antimicrobial chemotherapy. Lancet Infect Dis 2004, 4:611-619.
33. Gould I.M. Coping with antibiotic resistance: the impending crisis. Int J Antimicrob Agents 2010, 36(Suppl 3):S1-S2.